05Feb 2024
Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada

Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada

A recent study analyzing the impact of mepolizumab, the first widely available anti-interleukin five biologics, in a real-world Canadian healthcare setting revealed promising outcomes. The research, encompassing 275 patients, demonstrated that mepolizumab significantly reduced asthma exacerbations by 46.1%, asthma-related visits to general practitioners by 40.2%, specialist visits by 27.2%, and emergency department visits by 52.1%. Moreover, associated costs for these healthcare resources were markedly lower post-mepolizumab usage. These findings suggest that mepolizumab effectively decreases the burden of severe asthma in real-world scenarios, emphasizing its potential to improve patient outcomes and reduce healthcare costs.

  • #general medicine

Like

Save

Share